Large pharma at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

10 large pharma are at CTAD 2026 — 29 presentations on the program. Most represented: Johnson & Johnson Innovative Medicine (6 on the program), Roche (6 on the program), Eisai (5 on the program). 9 of them have their own page in this guide. As of Oct 8, 2026.

All 315 organizations at CTAD 2026 →

Showing 1–10 of 10 organizations

Organization	CTAD 2026 Attendance
Johnson & Johnson Innovative Medicine New Brunswick, New Jersey	◇Silver Sponsor
jnj.com Large pharmaSilver Sponsor Johnson & Johnson's pharmaceutical business; its Alzheimer's work includes the anti-tau antibody posdinemab and blood biomarkers for early detection.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Utility of Clinically Scalable Biomarkers for Prescreening in Preclinical Alzheimer’s Disease: Insights from RETAIN (P003) Blood and CSF biomarkers · Trial design and endpoints Talk Tue Nov 17 8:30am–9:10am Part of When Target Engagement Is Not Enough: Lessons from Posdinemab on Bridging Tau Biology to Clinical Outcomes Spatial Determinants of Posdinemab’s Effect on Tau PET Anti-amyloid and anti-tau therapies · PET and MRI imaging Talk Tue Nov 17 8:30am–9:10am Part of When Target Engagement Is Not Enough: Lessons from Posdinemab on Bridging Tau Biology to Clinical Outcomes CSF and Plasma Biomarker Changes After Anti-Tau Therapy: Fluid Biomarker Results from the Auτonomy Phase 2 Clinical Trial Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers Session Tue Nov 17 8:30am–9:10am When Target Engagement Is Not Enough: Lessons from Posdinemab on Bridging Tau Biology to Clinical Outcomes Anti-amyloid and anti-tau therapies Poster Wed Nov 18 7:15am–5:30pm Performance of Plasma and CSF biomarkers for tauPET staging in Alzheimer’s Disease: evidence from mass spectrometry and immunoassays in Autonomy (P252) Blood and CSF biomarkers · PET and MRI imaging Poster Wed Nov 18 7:15am–5:30pm Impact of epitope location on Tau antibody efficacy in inhibiting Tau-seeded aggregation (P330) Anti-amyloid and anti-tau therapies
Roche Basel, Switzerland
roche.com Large pharma Swiss drugmaker developing trontinemab, a Brainshuttle anti-amyloid antibody in phase 3 for early Alzheimer's disease.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Rationale and design of TARBELA-AD: A Phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of the NLRP3 inhibitor RG6434 in early symptomatic Alzheimer’s disease (P016) Other mechanisms and targets Talk Mon Nov 16 4:50pm–5:30pm Part of Visualizing the Brainshuttle™: Pioneering neuroimaging and mechanistic insights of amyloid clearance with trontinemab Trontinemab in Alzheimer’s disease – novel pharmacodynamic insights from the ongoing Phase Ib/IIa Brainshuttle™ AD study Anti-amyloid and anti-tau therapies Talk Mon Nov 16 4:50pm–5:30pm Part of Visualizing the Brainshuttle™: Pioneering neuroimaging and mechanistic insights of amyloid clearance with trontinemab Advanced imaging results from the Brainshuttle™ AD study with trontinemab in Alzheimer’s disease Anti-amyloid and anti-tau therapies · PET and MRI imaging Talk Tue Nov 17 9:10am–9:35am A Glimpse of the Future: How Diagnostics, Therapies, Trials, and Concepts of Prevention Must Evolve with Brigham and Women's Hospital Talk Tue Nov 17 2:35pm–3:15pm Part of Neuroinflammation in Alzheimer’s Disease: Targeting the NLRP3 Inflammasome and Neuroimmune Crosstalk The NLRP3 inflammasome as a therapeutic target in Alzheimer’s disease: biomarker, preclinical evidence and Phase I healthy participants’ safety data of the oral inhibitor RG6434 Other mechanisms and targets Poster Thu Nov 19 7:15am–5:00pm Clinical and operational determinants of amyloid-targeting therapies treatment initiation in early Alzheimer’s Disease: A discrete choice experiment (P394) Real-world data and access · Anti-amyloid and anti-tau therapies
Eisai Tokyo, Japan	◆Platinum Sponsor
eisai.com Large pharmaPlatinum Sponsor Japanese drugmaker that co-developed and markets lecanemab (Leqembi), an anti-amyloid antibody for early Alzheimer's disease, with Biogen.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Beyond Amyloid Clearance: CSF Proteomics Reveals Proteome-Wide CNS Remodeling Following Lecanemab Treatment (P007) Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers Poster Wed Nov 18 7:15am–5:30pm Impact of Blood-Based Biomarkers (BBMs) on Time to Treatment Initiation with Anti-Amyloid Therapies (AATs): A Retrospective Analysis Using the Optum Market Clarity Alzheimer’s Enriched Data (P248) Blood and CSF biomarkers · Real-world data and access Poster Wed Nov 18 7:15am–5:30pm Preferences and access considerations for clinical adoption of blood-based biomarker tests to confirm amyloid-β pathology in early Alzheimer’s disease: a 12-country survey (P294) Real-world data and access · Blood and CSF biomarkers Poster Wed Nov 18 7:15am–5:30pm Estimating the durability of residual effects on biomarkers after discontinuation of lecanemab (P319) Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers Talk Thu Nov 19 1:35pm Lecanemab Treatment and α-Synuclein Co-Pathology in the Clarity AD CSF Substudy Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers
Eli Lilly Indianapolis, Indiana	◆Platinum Sponsor
lilly.com Large pharmaPlatinum Sponsor Global drugmaker behind donanemab (Kisunla), an anti-amyloid antibody for early Alzheimer's, and the tau PET tracer flortaucipir.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Safety and Efficacy of Mevidalen in Alzheimer’s Disease: A Phase 2, Randomized, Double-Blinded Trial (P029) Other mechanisms and targets Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Evaluation of atrophy-defined subtypes in early symptomatic Alzheimer’s disease (P113) PET and MRI imaging Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Distinct Associations Between Hippocampal Subfield Volumes and Episodic Memory in Alzheimer’s Disease (P114) PET and MRI imaging Talk Thu Nov 19 11:05am The relationship between P-tau217 blood tests and neuropathology at autopsy in cognitively unimpaired individuals Blood and CSF biomarkers
MSD Rahway, New Jersey	◇Silver Sponsor
msd.com Large pharmaSilver Sponsor Global drugmaker, known as Merck & Co. in the US and Canada; its Alzheimer's pipeline includes the anti-tau antibody MK-2214.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue A Phase 2 Randomized, Controlled Trial of MK-1167, a Positive Allosteric Modulator of the α7 nAChR, as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia (P037) Other mechanisms and targets Poster Wed Nov 18 7:15am–5:30pm A Novel Plasma Biomarker Panel Assessed by NULISA Improves Amyloid Positivity Diagnosis Beyond pTau-217 for Clinical Trial Enrichment (P268) Blood and CSF biomarkers · Trial design and endpoints Talk Wed Nov 18 10:15am A phase 2 randomized, controlled trial of MK-2214, a novel antibody targeting pS413 tau, in early Alzheimer’s disease: Study rationale and design Anti-amyloid and anti-tau therapies
Biogen Cambridge, Massachusetts	◆Platinum Sponsor
biogen.com Large pharmaPlatinum Sponsor Neuroscience drugmaker that co-developed lecanemab (Leqembi) with Eisai and develops tau-targeting therapies, including an antisense drug.	Talk Tue Nov 17 4:45pm–5:25pm Additional biomarker and clinical findings from the Phase 2 CELIA study of diranersen in early Alzheimer’s disease Anti-amyloid and anti-tau therapies Poster Wed Nov 18 7:15am–5:30pm US Real-World Patterns of Amyloid Testing and Anti-Amyloid Therapy Initiation in Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI) (P259) Real-world data and access · Anti-amyloid and anti-tau therapies
Bristol Myers Squibb Princeton, New Jersey	◆Gold Sponsor
bms.com Large pharmaGold Sponsor Global drugmaker testing Cobenfy for psychosis in Alzheimer's disease and developing an anti-tau antibody, among other neuroscience programs.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Results from 2 phase 1 studies evaluating the dual FAAH/MAGL inhibitor irafamdastat in healthy adults (including Japanese and elderly) (P049) Other mechanisms and targets Poster Wed Nov 18 7:15am–5:30pm Temporal and Dose-Dependent Modulation of the Endocannabinoid System by Dual FAAH/MAGL Inhibition in Humans: Implications for Alzheimer’s Disease (P326) Other mechanisms and targets
Genentech South San Francisco, California
gene.com Large pharma Biotechnology company in the Roche group that discovers and develops medicines, including for neurological diseases such as Alzheimer's.	Poster Thu Nov 19 7:15am–5:00pm REACHED: Participant characteristics from a pilot pre-screening study designed to diversify clinical trial recruitment in understudied populations in Alzheimer’s disease (P437) Trial design and endpoints
Sanofi Paris, France	◇Silver Sponsor
sanofi.com Large pharmaSilver Sponsor French drugmaker; its Alzheimer's pipeline includes SAR448851, a TREM2 agonist tested in the phase 2 TREMHANCE trial.	Sponsor In the meeting’s sponsor directory, with no session on the public program
UCB Brussels, Belgium	◇Silver Sponsor
ucb.com Large pharmaSilver Sponsor Belgian biopharma developing bepranemab, an anti-tau antibody that completed a phase 2 trial in early Alzheimer's disease.	Sponsor In the meeting’s sponsor directory, with no session on the public program

Instantly find 20 buyers from large pharma

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction

Instantly find 20 buyers from large pharma

Browse CTAD 2026 by